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Abstract: The association between growth-hormone (GH) and neovascular retinopathies in 
nondiabetic patients has been reported in earlier series. We report occurrence of choroidal 
neovascularization (CNV) in a 15-year-old male patient undergoing long-term GH therapy. The 
CNV could be a consequence of the GH-intake in a susceptible myopic patient. 
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The role of growth hormone (GH) in human angiogenesis and retinal neovascularization 
has been demonstrated in recent years.1 The hormone is mitogenic for a variety of vas-
cular cells and thereby may exert regulatory functions in controlling metabolism and 
differentiated endothelial cell expression.2, 3 Herein we report occurrence of choroidal 
neovascularization (CNV) in a young patient undergoing long-term GH therapy.
Case report
A 15-year-old male patient presented with acute central vision loss OD. The patient 
had been taking daily dose of subcutaneous human GH (EutropinTM 4 UI/day) for the 
last 31 months due to early puberty and presumed diagnose of nanism. He had been 
also receiving monthly intramuscular doses of leuprolide (3.75 mg) for 24 months. Past 
ocular history was positive for myopia and his past medical history was unremarkable. 
Family history was positive for nanism.
His best-corrected visual acuity (BCVA) was 20/30 OS; his BCVA OD dropped 
from 20/30 to 20/100 with metamorphopsia. The spherical correction was −10.75 
diopter (D) OD and −9.75 D OS. Fundoscopy revealed myopic conus, peripapillary 
areas of retinal pigmented epithelium (RPE)-atrophy, but no detectable breaks in 
Bruch’s membrane. Fluorescein angiography disclosed early hyperﬂ  uorescence with 
late leakage corresponding to CNV OD (Figure 1). Optical coherence tomography 
disclosed RPE and neurosensory retina elevation due to sub-RPE CNV. The CNV 
OD regressed after photodynamic therapy and vision improved to 20/30 without 
metamorphopsia.
Comments
Growth hormone intake is widely used in the treatment of disorders with GH deﬁ  ciency 
such as nanism. We hypothesize that, in our patient, the CNV could be a consequence 
of the GH-intake in a susceptible myopic patient. High myopia can induce myopic 
degeneration as well as CNV, but usually in older patients mainly between 30 and 
50 years of age. However, even if CNV induced by myopia is usually more seen in 
adults, it can also be found in teenagers.4Clinical Ophthalmology 2009:3 90
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The association between GH and neovascular retinopathies 
in nondiabetic patients has been reported in earlier series.5 
GH may promote stimulation of CNV through a variety of 
mechanisms, while one recent hypothesis involves tumor 
necrosis factor-mediated endothelial cells proliferation.6
Growth hormone-replacement therapy for patients 
with GH deﬁ  ciency induces a diabetic-like retinopathy, 
which is attenuated after discontinuation of treatment.7 
Moreover, Hellström and colleagues showed that diabetic 
children with congenital GH deﬁ  ciency develop less retinal 
vascularization.8 Therefore, it is reasonable to speculate that 
GH level may have some relationship with CNV.
We describe occurrence of CNV in a young patient 
undergoing long-term GH therapy but, in this case, the role 
of GH in CNV formation is not deﬁ  nite because the effect of 
pathologic myopia can not be excluded. The link between iatro-
genic CNV due to growth hormone intake remains unknown.
Disclosure
The authors report no conﬂ  icts of interest in this work.
References
1.  Smith LEH, Kopchick JJ, Chen W, et al. Essential role of growth 
hormone in ischemia-induced retinal neovascularization. Science. 
1997;276:1706–9.
2.  Wright AD, Kohner EM, Oakley NW, et al. Serum growth hormone 
levels and the response of diabetic retinopathy to pituitary ablation. Br 
Med J. 1969;2:346–8.
3.  Lincoln DT, Singal PK, Al-Banaw A. Growth hormone in vascular 
pathology: neovascularization and expression of receptors is associated 
with cellular proliferation. Anticancer Res. 2007;27:4201–18.
4.  Bottoni F, Tilanus M. The natural history of juxtafoveal and subfo-
veal choroidal neovascularization in high myopia. Int Ophthalmol. 
2001;24:249–55.
5.  Koller EA, Green L, Gertner JM, et al. Retinal changes mimicking 
diabetic retinopathy in two nondiabetic, growth hormone-treated 
patients. J Clin Endocrinol Metab. 1998;83:2380–3.
6.  Andiran N, Yordam N. TNF-alpha levels in children with growth 
hormone deﬁ  ciency and the effect of long-term growth hormone 
replacement therapy. Growth Horm IGF Res. 2007;17:149–53.
7.  Hansen R, Koller EA, Malozowski S. Full remission of growth hor-
mone (GH)-induced retinopathy after GH treatment discontinuation: 
long-term follow-up. J Clin Endocrinol Metab. 2000;85:2627.
8.  Hellström A, Svensson E, Carlsson B, et al. Reduced retinal vascular-
ization in children with growth hormone deﬁ  ciency. J Clin Endocrinol 
Metab. 1999;84:795–8.
Figure 1 Fluorescein angiography demonstrated small inferior juxta-foveal choroidal neovascularization OD.